| P0 | Dog · Shoulder tumor | The lesion collapsed with dry necrosis. | No infection recorded. | Healed by day 30. |
| P1 | Cat · Subcutaneous mammary tumor | The lesion separated along a clearly defined plane. | No adverse event recorded. | Separated on day 7, re-epithelialized on day 20 and healed by day 40. |
| P2 | Dog · Mammary adenocarcinoma, three masses | The three masses developed necrosis on days 3–6. | No systemic toxicity recorded during follow-up. | Documented through day 6. |
| P4 | Dog · Oral sarcoma of the mandible | The record estimates 50%–75% shrinkage by day 7 and describes marked necrosis in the residual area after repeat treatment. | No adverse event recorded. | Appetite and activity improved in the record. |
| P5 | Dog · Oral malignant melanoma | The mass was estimated at about half its original size on day 3, with viable tissue in an area of incomplete coverage. | Death on day 11 in an animal with lung and liver metastases and cardiac disease. No necropsy was performed and the cause was undetermined. | Extensive necrosis and collapse on day 10. |
| P6 | Dog · Soft tissue sarcoma | CT showed several well-defined distribution zones. The mass later collapsed markedly. | Ulceration of the overlying skin. | No swelling or bleeding on day 1. Marked collapse on day 10. |
| P7 | Dog · Chest-wall sarcoma | The contour changed without measurable shrinkage in the record. | Overlying skin remained intact. | Contour assessed on day 12. |
| P8 | Dog · Tumor of the tongue and tongue base | Extensive necrosis was documented on day 2. The tongue and most of the tumor separated on day 4. | Tongue loss had been documented as anticipated before treatment. Tube feeding was used. | Most of the tumor bulk was gone after the second session, with small residual areas noted. |
| P9 | Dog · Recurrent oral melanoma | Estimated volume fell from about 28 mL to 15 mL with necrotic cavities. | No adverse event recorded. | An immediate color change was documented at the second session on day 18. |
| P10 | Cat · Forelimb squamous cell carcinoma | Bleeding stopped and a dry black scab formed in the treated region. | No adverse event recorded. | By day 20, regrowth was recorded only in the area of incomplete initial coverage. |
| P11 | Cat · Deep nasal tumor | CT-guided administration was completed. | No adverse event reported in the case table. | Follow-up was ongoing at the data cutoff. |
| P12 | Dog · Bilateral nasal tumor | CT documented distribution and an uncovered area. | Dark red nasal discharge the next day. | Walking was documented during recovery, followed by next-day observations. |
| P13 | Dog · Recurrent mandibular sarcoma | Most of the exposed surface darkened. Viable areas remained where coverage was incomplete. | No adverse event recorded. | Surface appearance documented at about 24 hours. |
| P14 | Dog · Bleeding oral tumor | Necrotic change was visible at about 15 minutes and bleeding stopped. | No adverse event recorded. | The case table records cancellation of the planned debulking and immediate observation. |
| P15 | Dog · Oral malignant tumor | The mass was estimated to shrink by about two-thirds at 30 hours. Normal eating was reported. | Fever and necrotic discharge on day 2 resolved after management. | Three sessions over about one month. The site was nearly flush with the mucosa at the third session. |
| P16 | Dog · Recurrent hindlimb tumor | Most of the tumor sloughed by day 8. | Edema and infection under the scab were recorded. The infection required debridement. | No visible residual after scab removal on day 21. |
| P17 | Dog · Vaginal and mammary tumors | The vaginal tumor surface dried and turned gray-yellow, with loss of visible vascular appearance. | No adverse event recorded in the case table. | The record primarily covers observations during delivery. |
| P18 | Dog · Prostate tumor | Direct observation documented persistent yellow discoloration. Hematuria stopped by day 6. | No adverse event recorded. All 15 reported chemistry values were within reference range on day 18. | Estimated volume decreased by about 42% by day 18. |
| P19 | Dog · Three adjacent mammary tumors | On day 2, the visible contact zone was smaller than the main tumor. The main tumor separated as a whole on day 9. The other two lesions also separated. | No infection recorded. | Healed in about three weeks. |
| P-MS | Dog · Multiple mammary tumors | Ultrasound documented visible delivery distribution in multiple lesions. | No adverse event reported. | The table primarily records imaging and observations at delivery. |
| P20 | Dog · Multicentric lymphoma | Ultrasound-guided delivery was completed in multiple larger masses. | Normal recovery and no abnormalities recorded through day 16. | Clinical observation through day 16. |
| P21 | Dog · Nasal mast cell tumor with adenoma | Post-treatment CT documented coverage of most of the tumor and some leakage. | Normal recovery recorded with no other adverse event in the case table. | Around day 10, the owner reported dark granular material expelled by sneezing. Follow-up CT was planned. |